CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL.
Cortes-Burgos LA, et al. Among authors: weir de.
Eur J Pharmacol. 2009 Sep 1;617(1-3):59-67. doi: 10.1016/j.ejphar.2009.06.058. Epub 2009 Jul 4.
Eur J Pharmacol. 2009.
PMID: 19580807